Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer by Chia‐Hsun Chu, Tzu‐Hsuan Chiu, Chin‐Chou Wang, Wen‐Chen Chang, Allen Chung‐Cheng Huang, Chien‐Ying Liu, Chih‐Liang Wang, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi S. Kuo, Cheng‐Ta Yang

Subjects: Get full text

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond by Fitzpatrick O, Naidoo J

Subjects: Get full text

PD‐L1 blockade by immune checkpoint inhibitors impairs sensitivity to osimertinib in EGFR‐mutant non‐small cell lung cancer cells by Dantong Sun, Puyuan Xing, Junling Li

Subjects: Get full text

Initial treatment efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma in clinical practice by Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Akihiro Morishita, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama

Subjects: “…durvalumab…”
Get full text

Phimosis: A rare complication of immunotherapy with durvalumab by Luis Gabriel Vázquez-Lavista, Luis Llorente, Jorge Alatorre-Alexander, José Arturo Ramírez-Muciño

Subjects: “…Durvalumab…”
Get full text

Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003) by Hidenobu Ishii, Koichi Azuma, Takayuki Shimose, Hiroshige Yoshioka, Takayasu Kurata, Naoki Shingu, Masaki Okamoto, Yosuke Kawashima, Isamu Okamoto

Subjects: Get full text

Safety and efficacy of durvalumab (MEDI4736) in various solid tumors by Yang H, Shen K, Zhu C, Li Q, Zhao Y, Ma X

Subjects: “…durvalumab…”
Get full text

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy by Emma Sanderson, Hari Wimaleswaran, Clare Senko, Shane White, Christine F. McDonald

Subjects: “…Durvalumab…”
Get full text

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circul... by Masahiro Torasawa, Hidehito Horinouchi, Shigehiro Yagishita, Hirofumi Utsumi, Keitaro Okuda, Daisuke Takekoshi, Saburo Ito, Hiroshi Wakui, Saori Murata, Sawako Kaku, Kae Okuma, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Jun Araya, Yuichiro Ohe, Yu Fujita

Subjects: Get full text

Longitudinal extensive transverse myelitis after chemoradiation therapy with durvalumab, a rare complication: case report by Travis Moodie, Ola Alshaqi, Abdul Alchaki

Subjects: “…Durvalumab…”
Get full text

Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature by N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, V. V. Breder, T. N. Borisova, D. I. Yudin, M. S. Ardzinba, A. V. Egorova, A. A. Fedorova

Subjects: Get full text

Cost-effectiveness of durvalumab plus tremelimumab in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer from the US healthcare sector’s and s... by Yena Gan, Fenghao Shi, Fenghao Shi, He Zhu, He Zhu, Huangqianyu Li, Huangqianyu Li, Sheng Han, Sheng Han, Duoduo Li

Subjects: Get full text

Trial watch: Immune checkpoint blockers for cancer therapy by Claire Vanpouille-Box, Claire Lhuillier, Lucillia Bezu, Fernando Aranda, Takahiro Yamazaki, Oliver Kepp, Jitka Fucikova, Radek Spisek, Sandra Demaria, Silvia C. Formenti, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Subjects: Get full text

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma by Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A

Subjects: “…Durvalumab…”
Get full text

Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization by Maaz Khan Afghan, Areeb Lutfi, Fatima Qadri, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Erika Hissong, Pashtoon Murtaza Kasi

Subjects: Get full text

The role of chemoradiotherapy and immunotherapy in stage III NSCLC by Zsuzsanna Orosz, Árpád Kovács

Subjects: Get full text

Durvalumab-induced triple-M syndrome by Femi Williams Adeoye, Nida Jaffar, Sanggeeta Surandran, Gulshad Begum, Mohammad Rafiqul Islam

Subjects: “…durvalumab…”
Get full text

Anti‐TIF1γ antibody‐positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers by Ryosuke Imai, Sumie Ikemura, Torahiko Jinta

Subjects: Get full text

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis by Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Lucia Rinaldi, Silvana Acquafredda, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso, Gennaro Palmiotti

Subjects: Get full text

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer by Jiahao Zhang, Jianying Lei, Caicong You, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li

Subjects: “…Durvalumab…”
Get full text